Terms: = Kidney tumors AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Treatment
22 results:
1. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract] [Full Text] [Related]
2. Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy.
Dong H; Cao Y; Jian Y; Lei J; Zhou W; Yu X; Zhang X; Peng Z; Sun Z
BMC Cancer; 2023 Oct; 23(1):943. PubMed ID: 37803307
[TBL] [Abstract] [Full Text] [Related]
3. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial.
Pal SK; Albiges L; Tomczak P; Suárez C; Voss MH; de Velasco G; Chahoud J; Mochalova A; Procopio G; Mahammedi H; Zengerling F; Kim C; Osawa T; Angel M; Gupta S; Khan O; Bergthold G; Liu B; Kalaitzidou M; Huseni M; Scheffold C; Powles T; Choueiri TK
Lancet; 2023 Jul; 402(10397):185-195. PubMed ID: 37290461
[TBL] [Abstract] [Full Text] [Related]
4. Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors.
Ishihara H; Ishiyama Y; Nemoto Y; Nakamura K; Tachibana H; Fukuda H; Yoshida K; Kobayashi H; Iizuka J; Shimmura H; Hashimoto Y; Tanabe K; Kondo T; Takagi T
Clin Genitourin Cancer; 2023 Feb; 21(1):136-145. PubMed ID: 36031535
[TBL] [Abstract] [Full Text] [Related]
5. Percutaneous microwave ablation under ultrasound guidance for renal cell carcinomas at clinical staging T1 in patients aged 65 years and older: A comparative study.
Cheng Z; Yu X; Han Z; Liu F; Yu J; Yang J; Ai D; Liang P
J Cancer Res Ther; 2022 Apr; 18(2):509-515. PubMed ID: 35645122
[TBL] [Abstract] [Full Text] [Related]
6. Prediction of drug candidates for clear cell renal cell carcinoma using a systems biology-based drug repositioning approach.
Li X; Shong K; Kim W; Yuan M; Yang H; Sato Y; Kume H; Ogawa S; Turkez H; Shoaie S; Boren J; Nielsen J; Uhlen M; Zhang C; Mardinoglu A
EBioMedicine; 2022 Apr; 78():103963. PubMed ID: 35339898
[TBL] [Abstract] [Full Text] [Related]
7. A novel nine-microRNA-based model to improve prognosis prediction of renal cell carcinoma.
Xu C; Zeng H; Fan J; Huang W; Yu X; Li S; Wang F; Long X
BMC Cancer; 2022 Mar; 22(1):264. PubMed ID: 35279104
[TBL] [Abstract] [Full Text] [Related]
8. Exposure-response analyses of cabozantinib in patients with metastatic renal cell cancer.
Krens SD; van Erp NP; Groenland SL; Moes DJAR; Mulder SF; Desar IME; van der Hulle T; Steeghs N; van Herpen CML
BMC Cancer; 2022 Mar; 22(1):228. PubMed ID: 35236333
[TBL] [Abstract] [Full Text] [Related]
9. Identification of potential biomarkers associated with immune infiltration in papillary renal cell carcinoma.
Deng R; Li J; Zhao H; Zou Z; Man J; Cao J; Yang L
J Clin Lab Anal; 2021 Nov; 35(11):e24022. PubMed ID: 34606125
[TBL] [Abstract] [Full Text] [Related]
10. How to Select the Optimal Candidates for Renal Mass Biopsy.
Martini A; Larcher A; Bravi CA; Capogrosso P; Falagario UG; Fallara G; Pellegrino F; Muttin F; Re C; Briganti A; Salonia A; Bertini R; Montorsi F; Capitanio U;
Eur Urol Oncol; 2021 Jun; 4(3):506-509. PubMed ID: 34074486
[TBL] [Abstract] [Full Text] [Related]
11. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
12. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Sati N; Boyne DJ; Cheung WY; Cash SB; Arora P
JAMA Netw Open; 2021 Jan; 4(1):e2034201. PubMed ID: 33496794
[TBL] [Abstract] [Full Text] [Related]
13. Identification of Four Pathological Stage-Relevant Genes in Association with Progression and Prognosis in Clear Cell Renal Cell Carcinoma by Integrated Bioinformatics Analysis.
Xu D; Xu Y; Lv Y; Wu F; Liu Y; Zhu M; Chen D; Bai B
Biomed Res Int; 2020; 2020():2137319. PubMed ID: 32309427
[TBL] [Abstract] [Full Text] [Related]
14. Gender-based psychological and physical distress differences in patients diagnosed with non-metastatic renal cell carcinoma.
Ajaj R; Cáceres JOH; Berlin A; Wallis CJD; Chandrasekar T; Klaassen Z; Ahmad AE; Leao R; Finelli A; Fleshner N; Goldberg H
World J Urol; 2020 Oct; 38(10):2547-2554. PubMed ID: 31893313
[TBL] [Abstract] [Full Text] [Related]
15. Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial.
Tannir NM; Msaouel P; Ross JA; Devine CE; Chandramohan A; Gonzalez GMN; Wang X; Wang J; Corn PG; Lim ZD; Pruitt L; Karam JA; Wood CG; Zurita AJ
Eur Urol Oncol; 2020 Oct; 3(5):687-694. PubMed ID: 31272939
[TBL] [Abstract] [Full Text] [Related]
16. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer.
Kishan AU; Cook RR; Ciezki JP; Ross AE; Pomerantz MM; Nguyen PL; Shaikh T; Tran PT; Sandler KA; Stock RG; Merrick GS; Demanes DJ; Spratt DE; Abu-Isa EI; Wedde TB; Lilleby W; Krauss DJ; Shaw GK; Alam R; Reddy CA; Stephenson AJ; Klein EA; Song DY; Tosoian JJ; Hegde JV; Yoo SM; Fiano R; D'Amico AV; Nickols NG; Aronson WJ; Sadeghi A; Greco S; Deville C; McNutt T; DeWeese TL; Reiter RE; Said JW; Steinberg ML; Horwitz EM; Kupelian PA; King CR
JAMA; 2018 Mar; 319(9):896-905. PubMed ID: 29509865
[TBL] [Abstract] [Full Text] [Related]
17. Long-Term Renal Outcomes after Cisplatin treatment.
Latcha S; Jaimes EA; Patil S; Glezerman IG; Mehta S; Flombaum CD
Clin J Am Soc Nephrol; 2016 Jul; 11(7):1173-1179. PubMed ID: 27073199
[TBL] [Abstract] [Full Text] [Related]
18. A randomised, phase II study of nintedanib or sunitinib in previously untreated patients with advanced renal cell cancer: 3-year results.
Eisen T; Loembé AB; Shparyk Y; MacLeod N; Jones RJ; Mazurkiewicz M; Temple G; Dressler H; Bondarenko I
Br J Cancer; 2015 Oct; 113(8):1140-7. PubMed ID: 26448178
[TBL] [Abstract] [Full Text] [Related]
19. Predictive impact of circulating vascular endothelial growth factor in four phase III trials evaluating bevacizumab.
Hegde PS; Jubb AM; Chen D; Li NF; Meng YG; Bernaards C; Elliott R; Scherer SJ; Chen DS
Clin Cancer Res; 2013 Feb; 19(4):929-37. PubMed ID: 23169435
[TBL] [Abstract] [Full Text] [Related]
20. Oncological outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: comparison over the three decades.
Adibi M; Youssef R; Shariat SF; Lotan Y; Wood CG; Sagalowsky AI; Zigeuner R; Montorsi F; Bolenz C; Margulis V
Int J Urol; 2012 Dec; 19(12):1060-6. PubMed ID: 22882743
[TBL] [Abstract] [Full Text] [Related]
[Next]
